49 patents currently held
3 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Jan 2027. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
4
Ending by 2030
Jan 2027
Next term end
33
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends no later than Aug 2035 · Medium confidence
Also notable
Ends Aug 2036 · Medium confidence
Also notable
Ends Aug 2029 · High confidence
Probes for Imaging Huntingtin Protein
US 11,059,836
Cited by 11 later US patents, top 25% of utility patents granted in 2021 in our data. Protection runs to 2035. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
Probes for Imaging Huntingtin Protein
US 11,344,637
Cited by 7 later US patents, top 25% of utility patents granted in 2022 in our data. Protection runs to 2036. A terminal disclaimer caps this term to an earlier patent's.
Certain KYNURENINE-3-Monooxygenase Inhibitors, Pharmaceutical Compositions, and Methods of Use Thereof
US 8,536,186
The most cited patent in this portfolio, cited by 34 later US patents, top 25% of utility patents granted in 2013 in our data. Protection runs to 2029.
Formerly held, still cited
Notable
Ends Jan 2027 · Medium confidence
Cited by 53 later US patents, top 10% of utility patents granted in 2015 in our data, and renewed at every maintenance window due so far. Protection runs to 2027.
now held by Ionis Pharmaceuticals, Inc.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 27, 2026The maintenance fee for Atm Kinase Inhibitors and Compositions and Methods of Use Thereof (US 11,685,734) comes due Dec 27, 2026. Unpaid by Jun 28, 2027, it lapses early.
- 3 fees due Apr 1 to 29, 2027 · next Apr 1
- 2 fees due May 7 to 19, 2027 · next May 7
- 2 fees due Jun 10 to 26, 2027 · next Jun 10
- 1 fee due Sep 5, 2027The maintenance fee for Heterocyclic Compounds and Imaging Agents for Imaging Huntingtin Protein (US 11,918,662) comes due Sep 5, 2027. Unpaid by Mar 6, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
The 5 largest of its 33 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Probes for Imaging Huntingtin Protein (2016) | 3 in force | to Aug 2036 |
| Probes for Imaging Huntingtin Protein (2017) | 3 in force | to Oct 2035 |
| Heterocyclic Compounds and Imaging Agents for Imaging Huntingtin Protein | 2 in force | to Jun 2041 |
| Compounds for Targeting Mutant Huntingtin Protein and Uses Thereof | 2 in force | to Feb 2040 |
| Probes for Imaging Huntingtin Protein (2017) | 2 in force | to Oct 2035 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,738,307 | Compositions and Their Uses Directed to Huntingtin In force · Medium confidence | In force | Medium confidence | |
| US 12,509,681 | Antisense Oligonucleotides Directed to Huntingtin In force · Medium confidence | In force | Medium confidence | |
| US 8,536,186 | Certain KYNURENINE-3-Monooxygenase Inhibitors, Pharmaceutical Compositions, and Methods of Use Thereof In force · High confidence | In force | High confidence | |
| US 8,946,197 | Transglutaminase TG2 Inhibitors, Pharmaceutical Compositions, and Methods of Use Thereof In force · High confidence | In force | High confidence | |
| US 8,883,785 | Certain KYNURENINE-3-Monooxygenase Inhibitors, Pharmaceutical Compositions, and Methods of Use Thereof In force · High confidence | In force | High confidence | |
| US 8,889,716 | Transglutaminase TG2 Inhibitors, Pharmaceutical Compositions, and Methods of Use Thereof In force · High confidence | In force | High confidence | |
| US 9,649,310 | Certain KYNURENINE-3-Monooxygenase Inhibitors, Pharmaceutical Compositions, and Methods of Use Thereof In force · High confidence | In force | High confidence | |
| US 10,442,782 | KYNURENINE-3-Monooxygenase Inhibitors, Pharmaceutical Compositions, and Methods of Use Thereof In force · Medium confidence | In force | Medium confidence | |
| US 10,501,433 | KYNURENINE-3-Monooxygenase Inhibitors, Pharmaceutical Compositions, and Methods of Use Thereof In force · Medium confidence | In force | Medium confidence | |
| US 9,505,736 | Histone Deacetylase Inhibitors and Compositions and Methods of Use Thereof In force · High confidence | In force | High confidence |
Also on record, not counted in the 49: 3 patents in force now held by others · 1 patent ended · 2 applications pending · 9 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.